Cancer Genetics (NASDAQ:CGIX) & Its Competitors Critical Analysis

Cancer Genetics (NASDAQ: CGIX) is one of 52 publicly-traded companies in the “Healthcare Facilities & Services” industry, but how does it contrast to its competitors? We will compare Cancer Genetics to similar businesses based on the strength of its earnings, valuation, dividends, risk, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

15.6% of Cancer Genetics shares are owned by institutional investors. Comparatively, 72.5% of shares of all “Healthcare Facilities & Services” companies are owned by institutional investors. 21.3% of Cancer Genetics shares are owned by insiders. Comparatively, 14.5% of shares of all “Healthcare Facilities & Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Cancer Genetics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cancer Genetics 0 1 2 0 2.67
Cancer Genetics Competitors 205 1448 2006 37 2.51

Cancer Genetics currently has a consensus price target of $6.00, indicating a potential upside of 103.39%. As a group, “Healthcare Facilities & Services” companies have a potential downside of 4.00%. Given Cancer Genetics’ stronger consensus rating and higher probable upside, research analysts clearly believe Cancer Genetics is more favorable than its competitors.

Risk and Volatility

Cancer Genetics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Cancer Genetics’ competitors have a beta of 0.86, meaning that their average share price is 14% less volatile than the S&P 500.

Earnings & Valuation

This table compares Cancer Genetics and its competitors revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Cancer Genetics $27.05 million -$15.80 million -3.04
Cancer Genetics Competitors $6.28 billion $211.91 million 365.30

Cancer Genetics’ competitors have higher revenue and earnings than Cancer Genetics. Cancer Genetics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Cancer Genetics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cancer Genetics -54.65% -51.22% -26.33%
Cancer Genetics Competitors 7.86% 2.21% 1.54%


Cancer Genetics competitors beat Cancer Genetics on 7 of the 12 factors compared.

Cancer Genetics Company Profile

Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.

Receive News & Ratings for Cancer Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply